

Supplementary Table 2. Summary of subject characteristics by vaccination group at enrollment.

	Group A ^a (Concomitant administration) N=526 n (%)	Group B ^a (Non-Concomitant administration) N=528 n (%)
Gender		
Male	262 (49.8)	264 (50.0)
Female	264 (50.2)	264 (50.0)
Age (Years)		
Mean (SD)	12.4 (1.2)	12.4 (1.2)
Median (Range)	12.0 (11 to 15)	12.0 (11 to 15)
Region		
Asia Pacific	71 (13.5)	69 (13.1)
Europe	455 (86.5)	459 (86.9)

^a Group A (concomitant administration) received a 0.5 mL dose of 9vHPV vaccine at day 1, month 2, and month 6 and a 0.5 mL dose of Tdap-IPV vaccine on day 1; Group B (non-concomitant administration) received 9vHPV vaccine as above and Tdap-IPV vaccine at month 1.